Skip to main content

Advertisement

SpringerLink
Log in

Evolving end points for clinical trials in advanced colorectal cancer

  • Published:
Current Colorectal Cancer Reports

Abstract

The treatment of advanced colorectal cancer has evolved significantly over recent years. The increasing and justified demand for timely and robust evaluation of emerging therapies has led to the careful evaluation of alternative end points for clinical trials beyond overall survival. This review offers insights into the advantages, limitations, and promise of existing and emerging efficacy end points of interest

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Yothers G: Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 2007, 25:5153–5154.

    Article  PubMed  Google Scholar 

  2. Buyse M, Molenberghs G, Burzykowski T, et al.: The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000, 1:49–67.

    Article  PubMed  Google Scholar 

  3. Buyse M, Burzykowski T, Carroll K, et al.: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007, 25:5218–5224.

    Article  CAS  PubMed  Google Scholar 

  4. Burzykowski T, Buyse M: Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 2006, 5:173–186.

    Article  PubMed  Google Scholar 

  5. Tang PA, Bentzen SM, Chen EX, Siu LL: Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007, 25:4562–4568.

    Article  PubMed  Google Scholar 

  6. Dodd LE, Korn EL, Freidlin B, et al.: Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 2008, 26:3791–3796.

    Article  PubMed  Google Scholar 

  7. Freidlin B, Korn EL, Hunsberger S, et al.: Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007, 25:2122–2126.

    Article  PubMed  Google Scholar 

  8. Panageas KS, Ben-Porat L, Dickler MN, et al.: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007, 99:428–432.

    Article  PubMed  Google Scholar 

  9. US Food and Drug Administration: Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics, 2007. Available at http://www.fda.gov/cber/gdlns/clintrialend.htm#iii. Accessed May 2009.

  10. Carroll KJ: Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 2007, 6:99–113.

    Article  PubMed  Google Scholar 

  11. Saltz LB, Clarke S, Diaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013–2019.

    Article  CAS  PubMed  Google Scholar 

  12. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.

    Article  CAS  PubMed  Google Scholar 

  13. Buyse M, Thirion P, Carlson RW, et al.: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373–378.

    Article  CAS  PubMed  Google Scholar 

  14. Louvet C, de Gramont A, Tournigand C, et al.: Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001, 91:2033–2038.

    Article  CAS  PubMed  Google Scholar 

  15. Grothey A, Hedrick EE, Mass RD, et al.: Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008, 26:183–189.

    Article  CAS  PubMed  Google Scholar 

  16. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228–247.

    Article  CAS  PubMed  Google Scholar 

  17. Tournigand C, Cervantes A, Figer A, et al.: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 2006, 24:394–400.

    Article  CAS  PubMed  Google Scholar 

  18. Falcone A, Ricci S, Brunetti I, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670–1676.

    Article  CAS  PubMed  Google Scholar 

  19. Delaunoit T, Alberts SR, Sargent DJ, et al.: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005, 16:425–429.

    Article  CAS  PubMed  Google Scholar 

  20. Blazer DG 3rd, Kishi Y, Maru DM, et al.: Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26:5344–5351.

    Article  PubMed  Google Scholar 

  21. Allegra C, Blanke C, Buyse M, et al.: End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007, 25:3572–3575.

    Article  PubMed  Google Scholar 

  22. Sargent DJ, Hayes DF: Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol 2008, 26:1922–1923.

    Article  PubMed  Google Scholar 

  23. Cohen SJ, Punt CJ, Iannotti N, et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213–3221.

    Article  PubMed  Google Scholar 

  24. Sargent DJ, Rubinstein L, Schwartz L, et al.: Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009, 45:290–299.

    Article  CAS  PubMed  Google Scholar 

  25. Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408–1417.

    Article  PubMed  Google Scholar 

  26. Tol J, Koopman M, Cats A, et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563–572.

    Article  CAS  PubMed  Google Scholar 

  27. Hecht JR, Mitchell E, Chidiac T, et al.: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672–680.

    Article  CAS  PubMed  Google Scholar 

  28. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007–1016.

    Article  CAS  PubMed  Google Scholar 

  29. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.

    Article  CAS  PubMed  Google Scholar 

  30. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23–30.

    Article  CAS  PubMed  Google Scholar 

  31. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229–237.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Daniel J. Sargent

Authors
  1. Sharlene Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Sargent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Sargent.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gill, S., Sargent, D.J. Evolving end points for clinical trials in advanced colorectal cancer. Curr colorectal cancer rep 5, 135–139 (2009). https://doi.org/10.1007/s11888-009-0020-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-009-0020-y

Keywords

Search

Navigation